Cytokine responses to human immunodeficiency virus type 1 (HIV-1) induced by immunization with live recombinant canarypox virus vaccine expressing HIV-1 genes boosted by HIV-1SF-2 recombinant GP120

Gorse, Geoffrey J.; Patel, Gira B.; Mandava, Mahendra; Arbuckle, J. Alan; Doyle, Tim; Belshe, Robert B.

doi:10.1016/s0264-410x(00)00378-9

Cited by 12 publications

(2 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Merely trying to answer a question about the protective role of the T H response does not seem to justify an experiment on this scale. Whether induction of T H responses by the gp120 component could enhance the breadth or magnitude of CTL responses to the ALVAC vector sufficiently could be answered rapidly by a small trial using methodology that was not available at the time of the earlier studies (4)(5)(6).…”

mentioning

confidence: 99%

A Sound Rationale Needed for Phase III HIV-1 Vaccine Trials

Burton

Desrosiers

Doms

et al. 2004

Science

122

View full text Add to dashboard Cite

mentioning

confidence: 99%

A Sound Rationale Needed for Phase III HIV-1 Vaccine Trials

Burton

Desrosiers

Doms

et al. 2004

Science

122

View full text Add to dashboard Cite

“…The ALVAC-HIV candidate vaccines induced HIV neutralizing antibodies in most vaccine recipients and CTL responses in a subset of vaccine recipients (10)(11)(12)(13)(14)(15)(16)(17)(18)(19). This induction occurred with or without a boost regimen using other Sanofi Pasteur (formerly Aventis Pasteur) vaccine candidates or HIV-1 recombinant gp120 vaccines.…”

mentioning

confidence: 99%

Phase I/II Randomized Trial of Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC-HIV (vCP1452) Prime/LIPO-5 Boost in Healthy, HIV-1-Uninfected Adult Participants

Frey

Peiperl

McElrath

et al. 2014

Clin. Vaccine Immunol.

Self Cite

View full text Add to dashboard Cite

rFinding an effective human immunodeficiency virus type 1 (HIV-1) vaccine remains a major global health priority. In a phase I/II, placebo-controlled trial, healthy, HIV-1-negative adults were randomized to receive one of 5 vaccine regimens: LIPO-5 (combination of 5 lipopeptides) alone (250 g), ALVAC-HIV (vCP1452) alone, or 3 groups of ALVAC-HIV (vCP1452) followed by ALVAC-HIV (vCP1452) plus LIPO-5 (250, 750, and 2,500 g). Only 73/174 participants (42%) received all four vaccinations due to a study halt related to myelitis. There were no significant differences in systemic reactions between groups or in local reactogenicity between groups receiving ALVAC-HIV (vCP1452). Significant differences in local reactogenicity occurred between groups receiving LIPO-5 (P < 0.05). Gag and Env antibodies were undetectable by ELISA 2 weeks after the fourth vaccination for all but one recipient. Antibodies to Gag and Env were present in 32% and 24% of recipients of ALVAC-HIV (vCP1452) alone and in 47% and 35% of ALVAC-HIV (vCP1452)؉LIPO recipients, respectively. Coadministration of LIPO-5 did not significantly increase the response rate compared to ALVAC-HIV (vCP1452) alone, nor was there a significant relationship between dose and antibody responses among ALVAC-HIV (vCP1452)؉LIPO groups. Over 90% of study participants had no positive gamma interferon (IFN-␥) enzyme-linked immunosorbent spot assay (ELISpot) responses to any peptide pool at any time point. The study was halted due to a case of myelitis possibly related to the LIPO-5 vaccine; this case of myelitis remains an isolated event. In general, there was no appreciable cell-mediated immunity detected in response to the vaccines used in this study, and antibody responses were limited. The clinical trial is registered on ClinicalTrials.gov with registry number NCT00076063.

show abstract